Current Report Filing (8-k)
2023年6月28日 - 5:31AM
Edgar (US Regulatory)
0000921114
false
0000921114
2023-06-27
2023-06-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June 27, 2023
ARMATA PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in
its charter)
Washington |
|
001-37544 |
|
91-1549568 |
(State or other jurisdiction
of incorporation or organization) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
4503 Glencoe Avenue
Marina del Rey, California |
|
90292 |
(Address of principal executive offices) |
|
(Zip Code) |
(310) 655-2928
(Registrant’s Telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of
the Act:
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange on Which Registered |
Common
Stock |
|
ARMP |
|
NYSE American |
Item 2.02 |
Shareholder Director Nominations. |
The information set forth under Item 8.01 regarding
the deadline for submitting proposals for director nominations is incorporated herein by reference.
Armata Pharmaceuticals, Inc. (“Armata”)
has set August 29, 2023 as the date for its 2023 annual meeting of stockholders (the “Annual Meeting”). The Annual Meeting
will be held at our principal executive offices at 4503 Glencoe Avenue, Marina del Ray, California 90292 at 8:30 a.m. local time. Armata’s
stockholders of record at the close of business on July 10, 2023, will be entitled to notice of the Annual Meeting and to vote upon matters
considered at the Annual Meeting.
Because the date of the Annual Meeting represents
a change of more than 30 days from the anniversary of Armata’s 2022 annual meeting of stockholders, Armata has set new deadlines
for (i) the receipt of stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (“Exchange
Act”), for inclusion in Armata’s proxy materials for the Annual Meeting (“Rule 14a-8 Deadline”) and (ii) receipt
of stockholder proposals and director nominations submitted pursuant to Article II, Section 2.6 of Armata’s Amended and Restated
Bylaws for consideration at the Annual Meeting (“Advance Notice Bylaws Provision Deadline”). The Rule 14a-8 Deadline is 5:00
p.m. (Eastern Time) on Friday, July 7, 2023, which Armata has determined to be a reasonable period of time before it expects to begin
to print and send its proxy materials. The Advance Notice Bylaws Provision Deadline is 5:00 p.m. (Eastern Time) on Friday, July 7, 2023.
Stockholder proposals and director nominations should be submitted in writing and must be received by the Corporate Secretary at Armata’s
principal executive offices at Armata Pharmaceuticals, Inc., 4503 Glencoe Avenue, Marina del Ray, California 90292, by the Rule 14a-8
Deadline or the Advance Notice Bylaws Provision Deadline, as applicable, in order to be considered timely.
Stockholder proposals submitted in accordance
with Rule 14a-8 of the Exchange Act must also comply with the remaining requirements of Rule 14a-8 of the Exchange Act in order to be
considered for inclusion in the proxy materials for the Annual Meeting.
Stockholder proposals and nominations submitted
pursuant to Armata’s advance notice bylaw provisions must also comply with the advance notice provisions contained in Armata’s
Amended and Restated Bylaws and may be omitted if not in compliance with applicable requirements. Stockholders are urged to read the complete
text of such advance notice provisions.
Item 9.01 |
Financial Statements and Exhibits. |
Exhibit
No. |
|
Description |
104 |
|
Cover Page Interactive Data File (embedded within Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 27, 2023 |
Armata Pharmaceuticals, Inc. |
|
|
|
By: |
/s/ Julianne Averill |
|
Name: |
Julianne Averill |
|
Title: |
Chief Financial Officer |
Armata Pharmaceuticals (AMEX:ARMP)
過去 株価チャート
から 8 2024 まで 9 2024
Armata Pharmaceuticals (AMEX:ARMP)
過去 株価チャート
から 9 2023 まで 9 2024